Viatris Inc. VTRS
Healthcare · Drug Manufacturers - Specialty & Generic · United States · S&P 500
Based on the available data, Viatris Inc. gets an algorithmic score of 58/100. It trades at 18.12 $, with a bullish technical trend (RSI 69.7) and 31.9% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (8.9%).
- Low valuation (P/E 6.8).
Weaknesses
- Low ROE (-2.8%).
- Thin net margin (-2.8%): vulnerable to costs.
- Shrinking revenue (-4.2% per year).
Fundamentals
| Forward P/E | 6.78 |
| PEG | 1.05 |
| P/B | 1.44 |
| EV/EBITDA | 7.67 |
| P/S | 1.41 |
| ROE % | -2.75 |
| ROA % | 2.67 |
| Gross margin % | 40.31 |
| Operating margin % | 12.55 |
| Net margin % | -2.79 |
| Revenue growth % (y/y) | 4.90 |
| Revenue CAGR % | -4.20 |
| Debt/Equity % | 95.53 |
| Current ratio | 1.58 |
| FCF yield % | 8.89 |
| Dividend yield % | 2.65 |
| Payout % | 960.00 |
Returns
| 1 month | +10.9 % |
| 3 months | +15.0 % |
| 6 months | +41.9 % |
| YTD | +48.9 % |
| 1 year | +97.1 % |
| 3 years | +113.2 % |
| 5 years | +68.4 % |
Risk
| 1-year volatility | 31.9 % |
| Beta | 0.74 |
| 5-year max drawdown | -45.7 % |
| Sharpe 1A | 2.16 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.